Deucravacitinib onset of action and maintenance of response in Phase 3 plaque psoriasis trials
J Dermatolog Treat 2024;35:2371045 doi: 10.1080/09546634.2024.2371045
The analysis of the POETYK PSO-1 and POETYK PSO-2 clinical trials showed that deucravacitinib 6mg QD displayed efficacy as early as 1 week, and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.